- Home
- ACRV
as 11-14-2024 10:30am EST
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 247.8M | IPO Year: | 2022 |
| Target Price: | $22.60 | AVG Volume (30 days): | 44.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.19 - $11.90 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acrivon Therapeutics Inc. News
ACRV Breaking Stock News: Dive into ACRV Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
a month ago
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
GlobeNewswire
a month ago
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
a month ago
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
MT Newswires
a month ago
Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316
GlobeNewswire
a month ago
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
MT Newswires
2 months ago
Ladenburg Thalmann Upgrades Acrivon Therapeutics to Buy From Neutral
GlobeNewswire
2 months ago
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Compare ACRV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRV Acrivon Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.